Abstract
90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.
| Original language | English (US) |
|---|---|
| Journal | Cancer Research |
| Volume | 55 |
| Issue number | 23 SUPPL. |
| State | Published - 1995 |
ASJC Scopus subject areas
- Cancer Research
- Oncology
Fingerprint Dive into the research topics of 'Prelabeling of chimeric monoclonal antibody L6 with<sup>90</sup>yttrium- and <sup>111</sup>indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy'. Together they form a unique fingerprint.
Cite this
Li, M., Meares, C. F., Salako, Q., Kukis, D. L., Zhong, G. R., Miers, L., & DeNardo, S. J. (1995). Prelabeling of chimeric monoclonal antibody L6 with90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Cancer Research, 55(23 SUPPL.).